Correction of iron deficiency in patients with abnormal uterine bleeding

Abstract

INTRODUCTION: Iron deficiency (ID) occurring latently or as iron deficiency anemia (IDA) is common in gynecology, particularly in patients with abnormal uterine bleeding (AUB).

AIM: We aimed at exploring the efficiency of a medication containing ferrous sulfate and multivitamins for the correction of latent ID and treatment of mild IDA in AUB patients.

MATERIALS AND METHODS: We performed a comprehensive clinical, laboratory, and instrumental examination of 60 women aged 35 to 50 years with AUB, revealing many gynecological pathologies (endometrial polyps or hyperplasia, ade nomyosis, and uterine myoma). The examined patients with AUB were divided into two groups: women with latent ID (group 1, n=38) and women with IDA (group 2, n=22). Moreover, all the patients had extragenital pathology in addition to gynecological diseases. As a treatment, ferrous sulfate with multivitamins was prescribed for 1–3 months.

RESULTS: Before treatment, the hemoglobin level in the examined patients ranged from 95 to 130 g/L, with an average of 127.1±1.8 g/L in group 1 and 100.3±2.1 g/L in group 2. Serum iron concentrations in the examined groups were 9.8±0.2 and 6.9±1.3 μmol/L, respectively. After treatment, the average levels of hemoglobin and serum iron increased significantly and reached normal levels in all those examined. Hemoglobin was 143.3±1.8 g/L in group 1 and 122.5±1.5 g/L in group 2, whereas serum iron was 14.9±0.2 μmol/L in group 1 and 13.5±1.0 μmol/L in group 2. Furthermore, a significant increase to normal values was observed in other indicators of complete blood count and biochemical analysis.

CONCLUSIONS: The results of the study reveal a high clinical efficiency of ferrous sulfate and multivitamins in the treatment of ID in patients with AUB.

Keywords

abnormal uterine bleeding / iron deficiency / iron deficiency anemia / medications with ferrous sulfate / ferrous sulfate with multivitamins

References

[1] Branca F, Mahy L, Mustafa TS. The lack of progress in reducing anaemia among women: the inconvenient truth. Bull World Health Organ. 2014;92(4):231. doi: 10.2471/BLT.14.137810

[2] Branca F., Mahy L., Mustafa T.S. The lack of progress in reducing anaemia among women: the inconvenient truth // Bull World Health Organ. 2014. Vol. 92, N 4. P. 231. doi: 10.2471/BLT.14.137810

[3] World Health Organization. The global prevalence of anaemia in 2011. Geneva: WHO; 2015. 48 p.

[4] World Health Organization. The global prevalence of anaemia in 2011. Geneva: WHO, 2015. 48 p.

[5] Radzinskiy VE, Galina TV, Dobretsova TA. The iron shield of reproductive health. Therapeutic strategies for iron deficiency anemia. Newsletter. Moscow: Editorial office of the journal StatusPraesens; 2015. 32 p. (In Russ).

[6] Радзинский В.Е., Галина Т.В., Добрецова Т.А. Железный щит репродуктивного здоровья. Терапевтические стратегии при железодефицитной анемии. Информационный бюллетень. Москва : Редакция журнала StatusPraesens, 2015. 32 с.

[7] Rumyantsev AG, Maschan AA, Chernov VM, Tarasova IS. Fede ral’nye klinicheskie rekomendatsii po diagnostike i lecheniyu zhelezodefitsitnoi anemii. Moscow; 2015. 43 p. (In Russ).

[8] Румянцев А.Г., Масчан А.А., Чернов В.М., Тарасова И.С. Федеральные клинические рекомендации по диагностике и лечению железодефицитной анемии. Москва, 2015. 43 с.

[9] Yaglov VV. Treatment of anemia in women with menstrual disorders. Gynecology. 2001;3(5):182–184. (In Russ).

[10] Яглов В.В. Лечение анемии у женщин с нарушением менструального цикла // Гинекология. 2001. Т. 3, № 5. С. 182–184.

[11] Dikke GB, Stuklov NI. Algorithms for the diagnosis and treatment of iron deficiency anemia and latent iron deficiency in women of reproductive age. Consensus of obstetrician-gynecologist and hematologist. Obstet Gynecol. 2020;(9 suppl.). (In Russ).

[12] Дикке Г.Б., Стуклов Н.И. Алгоритмы диагностики и лечения железодефицитной анемии и латентного дефицита железа у женщин репродуктивного возраста. Консенсус акушера-гинеколога и гематолога // Акушерство и гинекология. 2020. № 9 (приложение).

[13] Bolotova EV, Dudnikova AV, Krutova VA. Frequency and features of iron-deficient conditions in women of reproductive age. Klini cheskaya meditsina. 2020;98(4):287–293. (In Russ). doi: 10.34651/0023-2149-2020-98-4-287-293

[14] Болотова Е.В., Дудникова А.В., Крутова В.А. Частота и особенности железодефицитных состояний у женщин репродуктивного возраста // Клиническая медицина. 2020. Т. 98, № 4. С. 287–293. doi: 10.34651/0023-2149-2020-98-4-287-293

[15] Burlev VA, Konovodova EN, Ordzhonikidze NV, et al. Treatment of latent iron deficiency and iron deficiency anemia in pregnant wo men. Russian Bulletin of Obstetrician-Gynecologist. 2006;(1):64–68. (In Russ).

[16] Бурлев В.А., Коноводова Е.Н., Орджоникидзе Н.В., и др. Лечение латентного дефицита железа и железодефицитной анемии у беременных // Российский вестник акушера-гинеколога. 2006. № 1. C. 64–68.

[17] Mirza FG, Abdul-Kadir R, Breymann C, Fraser IS, Taher A. Impact and management of iron deficiency and iron deficiency anemia in women’s health. Expert Rev Hematol. 2018;11(9):727–736. doi: 10.1080/17474086.2018.1502081

[18] Mirza F.G., Abdul-Kadir R., Breymann C., Fraser I.S., Taher A. Impact and management of iron deficiency and iron deficiency anemia in women’s health // Expert Rev Hematol. 2018. Vol. 11, N 9. P. 727-736. doi: 10.1080/17474086.2018.1502081

[19] Fenules® (Fenules). Instructions for use [Internet]. VIDAL. Directory of medicines. [cited 2021 Aug 9]. (In Russ). Available from: https://www.vidal.ru/drugs/fenules_1286

[20] Фенюльс® (Fenules). Инструкция по применению. [Internet]. VIDAL. Справочник лекарственных средств. Дата обращения: 09.09.2021. Доступ по ссылке: https://www.vidal.ru/drugs/fenules_1286

[21] Fedorova TA, Borzykina OM, Strelnikova EV, Danilov AIu, Ivanets TIu. Correction of iron deficiency anemia in patients with me norrhagia. Russian Journal of Human Reproduction. 2017;23(4):50-55. (In Russ). doi: 10.17116/repro201723450-55

[22] Федорова Т.А., Борзыкина О.М., Стрельникова Е.В., Данилов А.Ю., Иванец Т.Ю. Коррекция железодефицитной анемии у пациенток с меноррагиями // Проблемы репродукции. 2017. Т. 23, № 4. С. 50–55. doi: 10.17116/repro201723450-55

[23] Tikhomirov AL, Sarsaniya SI. Uterine leiomyoma and IDA. Variant of preoperative preparation. Meditsinskiy sovet. 2019;(13):178–182. (In Russ). doi: 10.21518/2079-701X-2019-13-178-182

[24] Тихомиров А.Л., Сарсания С.И. Лейомиома матки и железодефицитная анемия. Вариант предоперационной подготовки // Медицинский Совет. 2019. № 13. С. 178–182.

[25] Prokhorenko TS, Zima AP, Saprina TS, et al. Significance of inflammation markers determined in pregnant women with anemic syndrome and obesity. Medical Immunology (Russia). 2018;20(5):639–646. (In Russ). doi: 10.15789/1563-0625-2018-5-639-646

[26] Прохоренко Т.С., Зима А.П., Саприна Т.С., и др. Значение определения маркеров воспаления у беременных с анемическим синдромом и ожирением // Медицинская иммунология. 2018. Т. 20, № 5. С. 639–646.

[27] Shalkharova ZhS, Shalkharova ZhN, Sadykova KZh, Nuskabaueva GO. Anemia in abdominal obesity and metabolic syndrome. Vestnik Almatinskogo gosudarstvennogo instituta usovershenstvovaniya vrachei. 2014;(3):59–62. (In Russ).

[28] Шалхарова Ж.С., Шалхарова Ж.Н., Садыкова К.Ж., Нускабаева Г.О. Анемии при абдоминальном ожирении и метаболическом синдроме // Вестник АГИУВ. 2014. № 3. С. 59–62.

RIGHTS & PERMISSIONS

Ozolinya L.A., Savchenko T.N., Golovko E.D.